Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 18, 2012

Mylan Pledges $500M to Expand Operations in Ireland Over Five Years

  • Mylan will invest up to $100 million a year over the next five years into expanding operations at its Galway and Dublin sites in Ireland, including enlarging R&D and manufacturing capacity within its respiratory, injectables, and oral solids franchises. Over 500 new jobs will be created, adding to the 700 employees Mylan already has in Ireland, where its Gerard Laboratories and Bioniche Pharma operations are based.

    The planned expansion of will be supported through financial incentives provided by the Irish government’s foreign investment agency IDA. “This investment in Mylan’s Irish operations and the growth of our capabilities in the country demonstrate our continued commitment to and confidence in our respiratory franchise and injectable platform, both of which are among Mylan’s many long-term growth drivers,” comments CEO Heather Bresch. “Ireland has also proven to be a valuable location for Mylan, providing the company with access to a skilled and highly educated workforce.” 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »